Feng J - Search Results

1

A novel aminopeptidase N inhibitor developed by virtual screening approach.

Feng J, Jin K, Zhu H, Zhang X, Zhang L, Liu J, Xu W. Feng J, et al. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5863-9. doi: 10.1016/j.bmcl.2012.07.086. Epub 2012 Aug 1. Bioorg Med Chem Lett. 2012. PMID: 22901392

2

Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.

Zhang Y, Feng J, Liu C, Zhang L, Jiao J, Fang H, Su L, Zhang X, Zhang J, Li M, Wang B, Xu W. Zhang Y, et al. Among authors: feng j. Bioorg Med Chem. 2010 Mar 1;18(5):1761-72. doi: 10.1016/j.bmc.2010.01.060. Epub 2010 Feb 6. Bioorg Med Chem. 2010. PMID: 20171895

3

LYP3, a new bestatin derivative for aminopeptidase N inhibition.

Luan Y, Ma C, Sui Z, Wang X, Feng J, Liu N, Jing F, Wang Y, Li M, Fang H, Xu W. Luan Y, et al. Among authors: feng j. Med Chem. 2011 Jan;7(1):32-6. doi: 10.2174/157340611794072706. Med Chem. 2011. PMID: 21235517

4

Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.

Feng J, Fang H, Wang X, Jia Y, Zhang L, Jiao J, Zhang J, Gu L, Xu W. Feng J, et al. Cancer Biol Ther. 2011 Mar 1;11(5):477-89. doi: 10.4161/cbt.11.5.14529. Epub 2011 Mar 1. Cancer Biol Ther. 2011. PMID: 21263218 Free article.

5

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

Zhang Y, Feng J, Jia Y, Wang X, Zhang L, Liu C, Fang H, Xu W. Zhang Y, et al. Among authors: feng j. J Med Chem. 2011 Apr 28;54(8):2823-38. doi: 10.1021/jm101605z. Epub 2011 Apr 5. J Med Chem. 2011. PMID: 21476600

6

Engineered Thermoplasma acidophilum factor F3 mimics human aminopeptidase N (APN) as a target for anticancer drug development.

Su J, Wang Q, Feng J, Zhang C, Zhu D, Wei T, Xu W, Gu L. Su J, et al. Among authors: feng j. Bioorg Med Chem. 2011 May 1;19(9):2991-6. doi: 10.1016/j.bmc.2011.03.028. Epub 2011 Mar 21. Bioorg Med Chem. 2011. PMID: 21493078

7

Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.

Zhang Y, Fang H, Feng J, Jia Y, Wang X, Xu W. Zhang Y, et al. Among authors: feng j. J Med Chem. 2011 Aug 11;54(15):5532-9. doi: 10.1021/jm200577a. Epub 2011 Jul 11. J Med Chem. 2011. PMID: 21714538

8

Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.

Zhang Y, Feng J, Liu C, Fang H, Xu W. Zhang Y, et al. Among authors: feng j. Bioorg Med Chem. 2011 Aug 1;19(15):4437-44. doi: 10.1016/j.bmc.2011.06.046. Epub 2011 Jun 21. Bioorg Med Chem. 2011. PMID: 21733698

9

Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.

Zhang Y, Feng J, Jia Y, Xu Y, Liu C, Fang H, Xu W. Zhang Y, et al. Among authors: feng j. Eur J Med Chem. 2011 Nov;46(11):5387-97. doi: 10.1016/j.ejmech.2011.08.045. Epub 2011 Sep 8. Eur J Med Chem. 2011. PMID: 21924799

10

Novel antileukemic agents derived from tamibarotene and nitric oxide donors.

Bian H, Feng J, Li M, Xu W. Bian H, et al. Among authors: feng j. Bioorg Med Chem Lett. 2011 Dec 1;21(23):7025-9. doi: 10.1016/j.bmcl.2011.09.103. Epub 2011 Oct 1. Bioorg Med Chem Lett. 2011. PMID: 22014829

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18,663 results

Search Page

Filters